What this is
- How it works
- How it works isn't classified yet
- How it’s given
- “Intervention: Biological: Boya IVIG Boya IVIG is a 5% human immunoglobulin for intravenous administration”In the company’s words, NCT06150833 on ClinicalTrials.gov
- Tested for
- Primary Immunodeficiency Disease
- Main trialPhase 3
- “The goal of this phase 3, open-label, single-group clinical trial is to assess the efficacy of Boya IVIG in maintaining the mean number of serious bacterial infections to less than one per year in participants with primary immunodeficiency (PYD) due to common variable immunodeficiency (CVID), as defined by the European Immunodeficiency Society (ESCID) / Pan American Immunodeficiency Group (PAGID), or X-linked agammaglobulinemia (XLA), as defined by molecular genetic testing (ESCID/PAGID). The safety and pharmacokinetics (PK) of the investigational product will also be evaluated.…”In the company’s words, NCT06150833 on ClinicalTrials.gov
- Other names
- IVIG · BOYA
Other drugs for Primary Immunodeficiency Disease
- PanzygaOctapharma · Phase 3
- IVIG-VImmuneVirchow Group · Phase 3
- DonidalorsenIonis Pharmaceuticals, Inc. · Phase 3
- Kedrion IVIG 10%Kedrion S.p.A. · Phase 3
- NavenibartAstria Therapeutics, Inc. · Phase 3
- DeucrictibantPharvaris Netherlands B.V. · Phase 3
Coming up1
- Sep 2028Phase 3 trial completes · ClinicalTrials.gov
Changes0
Last 90 daysNo changes yet. We started recording changes on 6 Nov 2026.
Trials1
| Trial | Phase | Completes | What it tests |
|---|---|---|---|
| Phase 3Not yet recruiting | Sep 2028 | IVIG Boya: Safety, Efficacy, and Pharmacokinetics |
A trial in both registries shows both numbers.
About
- Sources
- ClinicalTrials.gov updated 19 Nov 2026 · EU trials register (CTIS) updated 19 Nov 2026 · openFDA updated 19 Nov 2026